Printer Friendly

One less treatment option.

A rapidly increasing proportion of gonorrhea cases among men who have sex with men are resistant to a class of antibiotics commonly used to treat gonococcal infection, prompting the Centers for Disease Control and Prevention (CDC) to recommend that these drugs, fluoroquinolones, no longer be given as first-line treatment for this population. (1) According to a CDC study based on data from clinics in 23 cities, the proportion of men with gonorrhea whose infection was fluoroquinolone-resistant doubled overall between 2002 and 2003, but tripled among men who have sex with men. The rate for that group (5%) was 12 times the rate for men reporting only heterosexual behavior. In place of the oral antibiotics, the CDC is now recommending injectable alternatives for treating gonorrhea in men who have sex with men.

(1.) Centers for Disease Control and Prevention (CDC), Increasing cases of drug resistant gonorrhea prompt new treatment recommendation for gay and bisexual men, news release, Atlanta: CDC, Apr. 29, 2004.

FYI is compiled and written by Dore Hollander, executive editor of Perspectives on Sexual and Reproductive Health.
COPYRIGHT 2004 The Alan Guttmacher Institute
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FYI
Author:Hollander, Dore
Publication:Perspectives on Sexual and Reproductive Health
Geographic Code:1USA
Date:Jul 1, 2004
Words:178
Previous Article:Changes in teenagers' sexual behavior stall.
Next Article:Practitioners' perspectives on effective practices for Hispanic teenage pregnancy prevention.
Topics:


Related Articles
Flowers from the tropics.
How's the baby? (FYI).
If you sell it, will they come?
Minnesota students just say no to abstinence.
STD testing made easy.
Syphilis screening in pregnancy.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters